Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol

INTRODUCTION: Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%–20% of beta-cell function remaining at the time of diagnosis. Preservation of residual beta-cell function at diagnosis may improve glycaemic control and reduce longer-term complications. Immunotherapy has the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregory, John W, Carter, Kymberley, Cheung, Wai Yee, Holland, Gail, Bowen-Morris, Jane, Luzio, Stephen, Dunseath, Gareth, Tree, Timothy, Yang, Jennie Hsiu Mien, Marwaha, Ashish, Ali, Mohammad Alhadj, Bashir, Nadim, Hutchings, Hayley Anne, Fegan, Greg W, Stenson, Rachel, Hiles, Stephen, Marques-Jones, Susie, Brown, Amy, Tatovic, Danijela, Dayan, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524290/
https://www.ncbi.nlm.nih.gov/pubmed/34663658
http://dx.doi.org/10.1136/bmjopen-2021-049595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524290/
https://www.ncbi.nlm.nih.gov/pubmed/34663658
http://dx.doi.org/10.1136/bmjopen-2021-049595

Ejemplares similares